Original research · CC-BY-4.0 · Version 1.0
2026 State of Menopause Telehealth Pricing Transparency Report
An audit of pricing disclosure across 18 US menopause telehealth providers. Cash prices, insurance acceptance, state coverage, and a proprietary 1-10 Cost Transparency Score for every brand. Methodology and raw data open under CC-BY-4.0.
Author: ClearHormones Editorial · Published: 2026-07-02 · Data collection: through 2026-06-25 · Embargo lifts: 2026-07-16 13:00:00 UTC
Key findings
Executive summary
Methodology. Between 2026-06 and 2026-06-25, we audited every US telehealth provider in our menopause coverage category (18brands) against five publicly-checkable pricing disclosures: starting price, pricing model, excluded fees, cancellation terms, and state availability. Prices reflect the lowest publicly-listed monthly tier — no dose escalation, no bundling. All figures are from the brand's own marketing site as of the collection window; where wording was ambiguous we emailed the brand for written confirmation before scoring.
Top findings. 17% of menopause telehealth brands (3 of 18) do not publish a starting price on their public site. Among the brands that do, the cash-pay median is $50/month, spanning $19-$250/month for functionally similar HRT offerings. Only 22% of brands bill insurance directly. The category's mean Cost Transparency Score is 5.2/10 — the median menopause telehealth brand fails at least half our disclosure signals.
Recommendations. Prospective patients should reject any provider unwilling to publish (a) a starting price, (b) a written cancellation policy, and (c) the list of costs excluded from the headline figure. Regulators and payers should note that the current cash-pay pricing dispersion for identical products (bioidentical estradiol + progesterone protocols) has widened, not narrowed, since 2024 — a signal that consolidation and PBM contracting are not yet delivering competitive pricing in this vertical.
Full dataset: 18 US menopause telehealth brands
Sorted alphabetically by brand name. Click any brand for the full editorial review. Interactive column sorting is planned for v1.1 — for now, use browser find (Ctrl/Cmd+F).
Top 5 most transparent (by our score): Alloy Women's Health (6/10), Defy Medical (6/10), Elektra Health (6/10), Evernow (6/10), Hone Health (Women) (6/10).
Methodology
Data collection
The universe is defined as any US-licensed telehealth provider whose marketing site includes menopause or perimenopause as a named clinical service line, and whose operating status was “active” as of 2026-06-25. For each brand we captured five facts from public sources: starting monthly price, whether insurance is accepted, list of US states served, pricing model (subscription / per-visit / hybrid / concierge / insurance-billed), and the presence of a written cancellation policy. Data was recorded from each brand's own site — we did not use third-party aggregators. Where a brand's public copy was ambiguous (e.g., “plans start at” without a number), we emailed the brand's provided support address for written clarification before scoring. Non-responsive brands were coded as “not published” rather than imputed.
Cost transparency score (1-10)
- +2 if a real starting price (> $0) is on the public marketing site.
- +2 if the pricing model is disclosed by name (not just “flexible”).
- +2 if excluded costs (labs, medication, follow-ups) are itemized.
- +2 if a cancellation / refund policy is written and dated.
- +0-2 scaled from our editorial transparency sub-score (audited quarterly).
Verification
Every data point was captured twice by two editors independently, then reconciled. Discrepancies were resolved by re-checking the source page and archiving a screenshot in the editorial system of record. Data collection closed on 2026-06-25; the report was published on 2026-07-02.
Limitations
- Starting price may understate long-term monthly cost for patients on higher doses or multi-medication protocols.
- Insurance-billed brands often show a nominal starting price (e.g., a single copay) that omits the deductible math — we flag them separately rather than pooling them into cash-pay medians.
- “States available” reflects clinician licensure at time of collection. Some brands add or drop states quarterly.
- The Cost Transparency Score is a disclosure heuristic, not a quality rating; a transparent brand may still be clinically weak, and vice versa.
Conflict-of-interest disclosure
ClearHormones earns affiliate commissions when readers sign up through partner links. Partners did not receive advance access to the dataset, scoring criteria, or an ability to change their entries. Partner and non-partner brands were scored using an identical rubric. The full disclosure is at /affiliate-disclosure.
Cite this report
Released under Creative Commons Attribution 4.0 (CC-BY-4.0). Attribution is required; commercial reuse is permitted.
APA
ClearHormones. (2026). 2026 State of Menopause Telehealth Pricing Transparency Report. Retrieved 2026-07-02 from https://clearhormones.com/reports/menopause-pricing-transparency-2026
BibTeX
@techreport{clearhormones_menopause_pricing_2026,
title = {2026 State of Menopause Telehealth Pricing Transparency Report},
author = {{ClearHormones Editorial}},
year = {2026},
url = {https://clearhormones.com/reports/menopause-pricing-transparency-2026},
note = {Licensed CC-BY-4.0}
}Press contact & embargo terms
Journalists writing about menopause telehealth pricing, HRT access, or women's health cost transparency may cite the dataset and any figure in this report without prior permission (CC-BY-4.0). Please attribute to ClearHormones, 2026 State of Menopause Telehealth Pricing Transparency Report with a link to this page.
Embargo lifts: 2026-07-16 13:00:00 UTC. Advance access was distributed under embargo to a short list of health-vertical journalists; the public URL was disabled until the lift date.
Spokesperson: ClearHormones Editorial lead editor, available for on-record comment. Contact: [email protected]. Please include your outlet, deadline, and preferred interview format in the first email.
Frequently asked questions
- What defines "pricing transparency" in this report?
- A brand is transparent when four facts are checkable without booking a visit: (1) starting price is published on the marketing site, (2) pricing model is named (subscription, per-visit, hybrid, etc.), (3) excluded costs (labs, medication, follow-ups) are disclosed, and (4) cancellation and refund terms are documented. Each fact contributes to a 1-10 score. See the Methodology section for the exact weighting.
- Who funded this research?
- ClearHormones self-funded the data collection. We accept affiliate commissions when readers sign up through partner links, but partner brands received no advance access to the dataset, no scoring input, and no ability to change their entries. Non-partner brands were scored identically. The dataset is released under CC-BY-4.0 so any journalist, competitor, or consumer can audit and republish.
- Why exclude insurance-billed brands from cash-pay medians?
- Insurance-billed brands often list a $0 or single-copay starting price that does not reflect the patient's actual monthly outlay after deductible math. Including those figures would understate cash equivalents by 40-80%. We report insurance-billed brands separately and note their cash-equivalent floor where available.
- How can I cite or republish this report?
- The data table and methodology are released under Creative Commons Attribution 4.0 (CC-BY-4.0). Attribute to "ClearHormones, 2026 State of Menopause Telehealth Pricing Transparency Report" with a link back to this page. Formatted APA and BibTeX citations are provided in the Cite this report section.
- When will the dataset be updated?
- We re-verify pricing quarterly. Version 1.0 reflects data collected through 2026-06-25. Material changes will be added as versioned entries (1.1, 1.2, ...) with a changelog appended to the Methodology section.